RxDoctor Payments DataLook up a doctor →

Krupa Pandey, MD

Neurology · Albany, NYNPI 1255501508

Payments from drug & device makers

$3,758,776in general payments, 2019–2025

Across 975 payments — averaging $3855.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$1.8M
  • Novartis$818K
  • Sanofi$301K
  • E.r. Squibb & Sons, L.L.C.$287K
  • Biogen$167K
  • Bristol Myers Squibb$125K
  • plus $275K from 21 others
$13,686in research payments, 2019–2025

Across 8 payments — averaging $1710.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$13K
  • Sanofi$660

What the payments were for

  • Consulting fees$85,43220%
  • Speaking & faculty fees$318,88374%
  • Travel & lodging$13,4933%
  • Food & beverage$15,2394%
  • Education$3880%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,758,776 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$24,998
Medicare patients
73
Services billed
191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab48$452,777
AmpyraDalfampridine12$57,617
Glatiramer Acetate15$30,975
Dalfampridine ErDalfampridine39$13,449
Baclofen64$1,843
Teriflunomide14$626
Gabapentin17$361
Amitriptyline Hcl12$210

Paid to pharmacies, not to this prescriber.

Other neurology in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →